Clinical and demographic data of patients with PsA according to FCGR genotypes. Data are expressed as median (interquartile range); qualitative data as frequency (%).
| FCGR2A | FCGR3A | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic | All Patients, n = 103 | HH, n = 32 (31.1%) | HR, n = 49 (47.6%) | RR, n = 22 (21.4%) | VV, n = 21 (20.4%) | VF, n = 56 (54.4%) | FF, n = 26 (25.2%) |
| Age, yrs | 49.0 (41–59) | 47.5 (41–57) | 50.0 (43–56) | 45.5 (40–61) | 44.0 (38–49) | 49.0 (42.5–56) | 54.0 (42–62) |
| Female (%) | 49 (47.6) | 16 (50.0) | 19 (39.0) | 14 (64.0) | 9 (43.0) | 24 (43.0) | 16 (62.0) |
| PsA onset age, yrs | 35 (26–42) | 35 (27–42.5) | 36 (26–42) | 30.5 (24–50) | 30 (25–37) | 36.5 (26–42) | 37.5 (26–48) |
| PsA duration, yrs | 12 (8–17) | 13 (9–17) | 11 (8–17) | 12.5 (8–18) | 13 (10–15) | 11 (7–16.5) | 14 (10–20) |
| PsA pattern (%) | |||||||
| Peripheral* | 84 (81.6) | 23 (72.0) | 43 (88.0) | 18 (82.0) | 16 (76.0) | 46 (82.0) | 22 (85.0) |
| Mixed** | 19 (18.4) | 9 (28.0) | 6 (12.0) | 4 (18.0) | 5 (24.0) | 10 (18.0) | 4 (15.0) |
| TNF-α blocker used (%) | |||||||
| Infliximab | 34 (33.0) | 11 (34.0) | 15 (31.0) | 8 (33.0) | 9 (43.0) | 19 (34.0) | 6 (23.0) |
| Etanercept | 55 (53.4) | 16 (50.0) | 27 (55.0) | 12 (55.0) | 10 (48.0) | 28 (50.0) | 17 (65.0) |
| Adalimumab | 14 (13.6) | 5 (16.0) | 7 (14.0) | 2 (9.0) | 2 (10.0) | 9 (16.0) | 3 (12.0) |
| DAS28 | |||||||
| Baseline | 4.62 (3.78–5.46) | 4.59 (3.75–5.53) | 4.67 (4.00–5.29) | 4.54 (3.43–5.46) | 4.37 (3.68–4.91) | 4.68 (3.86–5.46) | 4.73 (3.82–5.60) |
| 3 mo | 2.46 (1.82–3.49) | 2.37 (1.87–3.23) | 2.65 (1.93–3.54) | 2.09 (1.73–3.07) | 2.16 (1.55–3.24) | 2.62 (1.82–3.56) | 2.34 (2.10–3.10) |
| 6 mo | 2.26 (1.73–3.44) | 2.44 (1.53–3.37) | 2.24 (1.82–3.43) | 2.40 (1.53–3.97) | 2.19 (1.55–2.94) | 2.23 (1.74–3.52) | 2.46 (2.03–3.39) |
↵* Peripheral: PsA patients with peripheral arthritis but without radiological sacroiliitis and inflammatory back pain.
↵** Mixed: PsA patients with peripheral arthritis and axial inflammation (sacroiliitis and inflammatory back pain). PsA: psoriatic arthritis; TNF-α: tumor necrosis factor-α; DAS28: 28-joint Disease Activity Score.